In this cohort at 12 months , those given prasugrel experienced significantly fewer ischemic events ( cardiovascular death , non-fatal myocardial infarction , or non-fatal stroke , 7.8 % vs 10.5 % , hazard ratio ( HR ) = 0.73 , p < 0.001 , than those given clopidogrel , with a non-significant increase in non-coronary artery bypass graft ( CABG ) TIMI major bleeding , 1.7 % vs 1.5 % , HR = 1.15 , p = 0.40 ; similarly , in the overall cohort these frequencies were 9.4 % vs 11.4 % , HR = 0.81 , p < 0.001 , for cardiovascular death , non-fatal myocardial infarction , or non-fatal stroke , and 2.2 % vs 1.8 % , HR = 1.24 , p = 0.10 , for non-CABG TIMI major bleeding .